What is potent acid inhibition, and how can it be achieved?

Drugs

Volumn 65, Issue SUPPL. 1, 2005, Pages 13-23

  Calvet, Xavier ^a   Gomollón, Fernando ^b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; ESOMEPRAZOLE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; STOMACH SECRETION INHIBITOR;

CORRELATION ANALYSIS; DNA POLYMORPHISM; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG TOLERABILITY; GENETICS; HEALING; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; NONHUMAN; REVIEW; STOMACH ACID SECRETION; STOMACH PH; ULCER;

HELICOBACTER; HELICOBACTER PYLORI;

EID: 30344474594     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200565001-00004     Document Type: Review

References (92)

1. Koelz HR. Gastric acid in vertebrates. Scand J Gastroenterol 1992; 27 Suppl. 193: 2-6
2. Tyler MJ, Shearman DJC, Franco R, et al. Inhibition of gastric acid secretion in the gastric brooding frog, Rheobatrachus silus. Science 1983; 220: 609-10
3. Burget DW, Chiverton SG, Hunt RH. Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression. Gastroenterology 1990; 99: 345-51
4. Forte JG, Wolosin JM. HCL secretion by the gastric oxyntic cell. In: Johnson LR, editor. Physiology of the gastrointestinal tract 2nd ed. New York: Raven Press; 1987. 853-62
5. Bamberg P, Caswell CM, Frame MH, et al. A meta-analysis comparing the efficacy of omeprazole with H2-receptor antagonists for acute treatment of duodenal ulcer in Asian patients. J Gastroenterol Hepatol 1992; 7: 577-85
6. Eriksson S, Langstrom G, Rikner L, et al. Omeprazole and H2-receptor antagonists in the acute treatment of duodenal ulcer, gastric ulcer and reflux oesophagitis: a meta-analysis. Eur J Gastroenterol Hepatol 1995; 7: 467-75
7. Gisbert JP, Gonzalez L, Calvet X, et al. Proton pump inhibitors versus H2-antagonists: a meta-analysis of their efficacy in treating bleeding peptic ulcer. Aliment Pharmacol Ther 2001; 15: 917-26
8. Gisbert JP, Khorrami S, Calvet X, et al. Meta-analysis: proton pump inhibitors vs. H2-receptor antagonists - their efficacy with antibiotics in Helicobacter pylori eradication. Aliment Pharmacol Ther 2003; 18: 757-66
9. Poynard T, Lemaire M, Agostini H. Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer. Eur J Gastroenterol Hepatol 1995; 7: 661-5
10. Hunt RH. The relationship between the control of pH and healing and symptom relief in gastro-esophageal reflux disease. Aliment Pharmacol Ther 1995; 9: 15-25
11. Chiba N, De Gara CJ, Wilkinson JM, et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112: 1798-810
12. Hirschowitz BI. A critical analysis, with appropriate controls, of gastric acid and pepsin secretion in clinical esophagitis. Gastroenterology 1991; 101: 1149-58
13. Orlando RC. Why is the high grade inhibition of gastric acid secretion afforded by proton-pump inhibitors often required for healing of reflux esophagitis? An epithelial perspective. Am J Gastroenterol 1996; 91: 1692-6
14. Holloway RH, Dent J, Narielvala F, et al. Relation between esophageal acid exposure and healing of oesophagitis with omeprazole in patients with severe reflux esophagitis. Gut 1996; 38: 649-54
15. Klikenberg-Knol EC, Festen HPM, Jansen JBMJ, et al. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med 1994; 121: 161-7
16. Gardner JD, Sloan S, Miner PB, et al. Determination of the reduction in gastric acidity necessary to prevent pathological oesophageal reflux in patients with gastro-oesophageal reflux disease treated with a proton pump inhibitor. Aliment Pharmacol Ther 2003; 17: 955-64
17. Hatlebakk JG. Review article: gastric acidity - comparison of esomeprazole with other proton pump inhibitors. Aliment Pharmacol Ther 2003; 17 Suppl. 1: 10-5
18. Howden CW, Jones DB, Peace KE, et al. The treatment of gastric ulcer with antisecretory drugs. Relationship of pharmacological effect to healing rates. Dig Dis Sci 1988; 33: 619-24
19. Miller LS, Vinayek R, Frucht H, et al. Reflux esophagitis in patients with Zollinger-Ellison syndrome. Gastroenterology 1990; 98: 341-6
20. Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors - emphasis on rabeprazole. Aliment Pharmacol Ther 1999; 13 Suppl. 3: 27-36
21. Verdu EF, Armstrong D, Idstrom JP, et al. Intragastric pH during treatment with omeprazole: role of Helicobacter pylori and H. pylori-associated gastritis. Scand J Gastroenterol 1996; 31: 1151-6
22. Labenz J, Tillenburg B, Peitz U, et al. Effect of curing Helicobacter pylori infection on intragastric acidity during treatment with ranitidine in patients with duodenal ulcer. Gut 1997; 41: 33-6
23. Labenz J, Tillenburg B, Peitz U, et al. Efficacy of omeprazole one year after cure of Helicobacter pylori infection in duodenal ulcer patients. Am J Gastroenterol 1997; 92: 576-81
24. Williams MP, Usselmann B, Chilton A, et al. Eradication of Helicobacter pylori increases nocturnal intragastric acidity during dosing with rabeprazole, omeprazole, lansoprazole and placebo. Aliment Pharmacol Ther 2003; 17: 775-83
25. Hawkey CJ, Naesdal J, Wilson I, et al. Relative contribution of mucosal injury and Helicobacter pylori in the development of gastroduodenal lesions in patients taking non-steroidal anti-inflammatory drugs. Gut 2002; 51: 336-43
26. Graham DY. Critical effect of Helicobacter pylori infection on the effectiveness of omeprazole for prevention of gastric or duodenal ulcers among chronic NSAID users. Helicobacter 2002; 7: 1-8
27. Scheiman JM, Vakil N, Hawkey CJ, et al. Esomeprazole prevents gastric and duodenal ulcers in at-risk patients on continuous non-selective or Cox-2 selective NSAID therapy. Gastroenterology 2004; 126: A82
28. El Omar EM, Carrington M, Chow WH, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000; 404: 398-402
29. Take S, Mizuno M, Ishiki K, et al. Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection. Am J Gastroenterol 2003; 98: 2403-8
30. Furuta T, Shirai N, Xiao F, et al. Polymorphism of interleukin-1beta affects the eradication rates of Helicobacter pylori by triple therapy. Clin Gastroenterol Hepatol 2004; 2: 22-30
31. Labenz J, Stolte M, Blum AL, et al. Intragastric acidity as a predictor of the success of Helicobacter pylori eradication: a study in peptic ulcer patients with omeprazole and amoxicillin. Gut 1995; 37: 39-43
32. Vallve M, Vergara M, Gisbert JP, et al. Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis. Aliment Pharmacol Ther 2002; 16: 1149-56
33. Plachetka J, Morelli G, Hines C, et al. Integrated gastric acidity can predict the prevention of naproxen-induced gastroduodenal pathology in normal subjects. Gastroenterology 2003; 123: 510
34. Pursnani KG, Mohiuddin MA, Geisinger KR, et al. Experimental study of acid burden and acute oesophagitis. Br J Surg 1998; 85: 677-80
35. Smith JL, Opekun AR, Larkai E, et al. Sensitivity of the esophageal mucosa to pH in gastroesophageal reflux disease. Gastroenterology 1989; 96: 683-9
36. Motomura A, Seo M, Sakurai T, et al. Predictable factors in healing of gastric ulcer, comparative analysis of local morphologic factor of gastric ulcer and suppression of intragastric pH. Nippon Shokakibyo Gakkai Zasshi 1995; 92: 769-79
37. Abe Y, Inamori M, Togawa J, et al. The comparative effects of single intravenous doses of omeprazole and famotidine on intragastric pH. J Gastroenterol 2004; 39: 21-5
38. Hsu TC, Su CF, Leu SC, et al. Omeprazole is more effective than a histamine H2-receptor blocker for maintaining a persistent elevation of gastric pH after colon resection for cancer. Am J Surg 2004; 187: 20-3
39. Shirai N, Furuta T, Xiao F, et al. Comparison of lansoprazole and famotidine for gastric acid inhibition during the daytime and night-time in different CYP2C19 genotype groups. Aliment Pharmacol Ther 2002; 16: 837-46
40. Blum RA, Shi H, Karol MD, et al. The comparative effects of lansoprazole, omeprazole, and ranitidine in suppressing gastric acid secretion. Clin Ther 1997; 19: 1013-23
41. Armbrecht U, Abucar A, Hameeteman W, et al. Treatment of reflux oesophagitis of moderate and severe grade with ranitidine or pantoprazole - comparison of 24-hour intragastric and oesophageal pH. Aliment Pharmacol Ther 1997; 11: 959-65
42. Takeda H, Hokari K, Asaka M. Evaluation of the effect of lansoprazole in suppressing acid secretion using 24-hour intragastric pH monitoring. J Clin Gastroenterol 1995; 20 Suppl. 1: S7-9
43. Sugiyama M, Aoki T, Matsuo Y. Determining the optimal dose of lansoprazole injection by 24-hour intragastric pH monitoring. J Clin Gastroenterol 1995; 20 Suppl. 2: S14-6
44. Hurlimann S, Abbuhl B, Inauen W, et al. Comparison of acid inhibition by either oral high-dose ranitidine or omeprazole. Aliment Pharmacol Ther 1994; 8: 193-201
45. Teyssen S, Stephan F, Singer MV. Comparison of the effect of a 28-day long-term therapy with the proton pump inhibitor pantoprazole with the H2-receptor antagonist ranitidine on intragastric pH in healthy-human subjects. Gastroenterology 1995; 108: A240
46. Houben GM, Hooi J, Hameeteman W, et al. Twenty-fourhour intragastric acidity: 300 mg ranitidine b.d., 20 mg omeprazole o.m., 40 mg omeprazole o.m. vs. placebo. Aliment Pharmacol Ther 1995; 9: 649-54
47. Lachman L, Lukasik N, Greski-Rose PA, et al. Tachyphylaxis: evidence from phase I study in support of treatment with a PPI. Gastroenterology 1999; 116: A227
48. Meyer M, Meier R, Drewe J. Effect of lansoprazole and ranitidine on gastric acidity in healthy volunteers. Gastroenterology 1997; 112: A219
49. Rohss K, Wilder-Smith C, Naucler E, et al. Esomeprazole 20 mg provides more effective intragastric acid control than maintenance-dose rabeprazole, lansoprazole or pantoprazole in healthy volunteers. Clin Drug Invest 2004; 24: 1-7
50. Wilder-Smith C, Claar-Nilson C, Hasselgreen G, et al. Esomeprazole 40 mg provides faster and more effective acid control than rabeprazole 20 mg in patients with symptoms of GERD [abstract]. Am J Gastroenterol 2001; 96 Suppl. 5: S45
51. Wilder-Smith CH, Rohss K, Nilsson-Pieschl C, et al. Esomeprazole 40 mg provides improved intragastric acid control as compared with lansoprazole 30 mg and rabeprazole 20 mg in healthy volunteers. Digestion 2003; 68: 184-8
52. Wilder-Smith CH, Schindler D, Rohss K. The influence of cytochrome P450 2C19 metabolizer genotype on the antisecretory effects of Esomeprazole, Lansoprazole, Pantoprazole and Rabeprazole. Gastroenterology 2004; 124: 338.
53. Baisley K, Warrington S, Tejura B, et al. Rabeprazole 20 mg compared with esomeprazole 40 mg in the control of intragastric pH in healthy volunteers. Gastroenterology 2002; 122: A199
54. Warrington S, Baisley K, Boyce M, et al. Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24-h intragastric pH and serum gastrin in healthy subjects. Aliment Pharmacol Ther 2002; 16: 1301-7
55. Miner P Jr, Katz PO, Chen Y, et al. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003; 98: 2616-20
56. Isakov VA, Morozov SV, Tsodikova OM, et al. Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24-h intragastric pH in H. pylori positive PPI extensive metabolizers. Gastroenterology 2004; 124: A340
57. Wilder-Smith C, Lind T, Lundin C, et al. Comparison of esomeprazole (20, 40, 80 mg) versus lansoprazole (15, 30 and 60 mg) on intragastric pH in healthy subjects. Gastroenterology 2003; 124: A444
58. Thomson ABR, Claar-Nilson C, Hasselgreen G, et al. Esomeprazole 40 mg provides more effective acid control than lansoprazole 30 mg during single and repeated administration [abstract]. Gut 2000; 47 Suppl. II: A63
59. Rohss K, Hasselgren G, Hedenstrom H. Effect of esomeprazole 40 mg vs omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease. Dig Dis Sci 2002; 47: 954-8
60. Lind T, Rydberg L, Kyleback A, et al. Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000; 14: 861-7
61. Armstrong D, Bair D, James C, et al. Oral esomeprazole vs. intravenous pantoprazole: a comparison of the effect on intragastric pH in healthy subjects. Aliment Pharmacol Ther 2003; 18: 705-11
62. Wilder-Smith C, Rohss K, Lundin C, et al. Esomeprazole (E) 40 mg provides more effective acid control than pantoprazole (P) 40 mg. Gastroenterology 2000; 118: A22-3
63. Pantoflickova D, Dorta G, Ravic M, et al. Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Aliment Pharmacol Ther 2003; 17: 1507-14
64. Adachi K, Katsube T, Kawamura A, et al. CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole. Aliment Pharmacol Ther 2000; 14: 1259-66
65. Tutuian R, Katz PO, Castell DO. A PPI is a PPI is a PPI; lessons from prolonged intra-gastric pH monitoring. Gastroenterology 2000; 118: A17
66. Saitoh T, Fukushima Y, Otsuka H, et al. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers. Aliment Pharmacol Ther 2002; 16: 1811-7
67. Shirai N, Furuta T, Moriyama Y, et al. Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment Pharmacol Ther 2001; 15: 1929-37
68. Van Nieumenhoven M, De Beus E, Bours A, et al. Efficacy of 20 mg oral rabeprazole vs. 40 mg omeprazole intravenously on 24 h gastric pH in healthy volunteers: a randomized, double-blind, placebo-controlled, cross-over study. Gastroenterology 2003; 124: A230-1
69. Ke MY, Wang ZF, Luo JY, et al. Efficacy of rabeprazole versus omeprazole for acid suppression in patients with duodenal ulcer: a multicenter, randomized, double-blind clinical trial. Gastroenterology 2003; 124: A445
70. des Varannes SB, Bonnot-Marlier S, Bicheler V, et al. Rabeprazole 10 mg induces a faster and stronger control of diurnal and nocturnal gastric acidity than omeprazole 10 mg and decreases nocturnal acid breakthrough (NAB) amplitude. Gastroenterology 2002; 122: A201-2
71. Williams MP, Sercombe J, Hamilton MI, et al. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment Pharmacol Ther 1998; 12: 1079-89
72. Katz PO, Xue S, Castell DO. Control of intragastric pH with omeprazole 20 mg, omeprazole 40 mg and lansoprazole 30 mg. Aliment Pharmacol Ther 2001; 15: 647-52
73. Katz PO, Hatlebakk JG, Castell DO. Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole. Aliment Pharmacol Ther 2000; 14: 709-14
74. Thoring M, Hedenstrom H, Eriksson LS. Rapid effect of lansoprazole on intragastric pH: a crossover comparison with omeprazole. Scand J Gastroenterol 1999; 34: 341-5
75. Geus WP, Mulder PG, Nicolai JJ, et al. Acid-inhibitory effects of omeprazole and lansoprazole in Helicobacter pylori-negative healthy subjects. Aliment Pharmacol Ther 1998; 12: 329-35
76. Brummer RJ, Geerling BJ, Stockbrugger RW. Initial and chronic gastric acid inhibition by lansoprazole and omeprazole in relation to meal administration. Dig Dis Sci 1997; 42: 2132-7
77. Tolman KG, Sanders SW, Buchi KN, et al. The effects of oral doses of lansoprazole and omeprazole on gastric pH. J Clin Gastroenterol 1997; 24: 65-70
78. Timmer W, Ripke H, Kleist P, et al. Effect of four lansoprazole dose levels and one dosage regimen of omeprazole on 24-hour intragastric pH in healthy subjects. Methods Find Exp Clin Pharmacol 1995; 17: 489-95
79. Verdu EF, Fraser R, Armstrong D, et al. Effects of omeprazole and lansoprazole on 24-hour intragastric pH in Helicobacter pylori-positive volunteers. Scand J Gastroenterol 1994; 29: 1065-9
80. Bruley des Varannes S, Levy P, Lartigue S, Dellatolas F, Lemaire M, Galmiche JP. Comparison of lansoprazole with omeprazole on 24-hour intragastric pH, acid secretion and serum gastrin in healthy volunteers. Aliment Pharmacol Ther 1994; 8: 309-14
81. Meyer M, Meier R, Mitlodi HM. Effect of low-dose lansoprazole and omeprazole on gastric acidity in Helicobacter pylori-negative volunteers. Gastroenterology 1998; 114: A227
82. Florent C, Akrour O, Joubert M. Comparison of the effects of lansoprazole and omeprazole on gastric pH profile in healthy volunteers. Gastroenterology 1993; 104: A79
83. Seensalu R, Iwarzon M, Janczewska I, et al. Dose-response comparison of lansoprazole and omeprazole on 24-hour gastric-acidity and plasma gastrin in healthy-volunteers. Gastroenterology 1995; 108: A215
84. Wilder-Smith CH, van Niekerk N, Scholtz HE. How much is the action of different proton pump inhibitors affected by the time of dosing relative to food ingestion? Gastroenterology 1999; 116: A353
85. Janczewska I, Sagar M, Sjostedt S, et al. Comparison of the effect of lansoprazole and omeprazole on intragastric acidity and gastroesophageal reflux in patients with gastroesophageal reflux disease. Scand J Gastroenterol 1998; 33: 1239-43
86. Florent C, Forestier S. Twenty-four-hour monitoring of intragastric acidity: comparison between lansoprazole 30 mg and pantoprazole 40 mg. Eur J Gastroenterol Hepatol 1997; 9: 195-200
87. Meyer M, Meier R, Mitlodi HM. Effect of lansoprazole and pantoprazole on gastric acidity in Helicobacter pylori negative volunteers. Gastroenterology 1998; 114: A226-7
88. Huang JQ, Goldwater DR, Thomson AB, et al. Acid suppression in healthy subjects following lansoprazole or pantoprazole. Aliment Pharmacol Ther 2002; 16: 425-33
89. Taubel JJ, Sharma VK, Chiu YL, et al. A comparison of simplified lansoprazole suspension administered nasogastrically and pantoprazole administered intravenously: effects on 24-h intragastric pH. Aliment Pharmacol Ther 2001; 15: 1807-17
90. Freston J, Chiu YL, Pan WJ, et al. Effects on 24-hour intragastric pH: a comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously. Am J Gastroenterol 2001; 96: 2058-65
91. Hartmann M, Theiss U, Huber R, et al. Twenty-four-hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole. Aliment Pharmacol Ther 1996; 10: 359-66
92. Brunner G, DanzNeeff H, Athmann C, et al. Comparison of pantoprazole (40 mg sid) versus omeprazole (40 mg sid) on intragastric pH and serum gastrin in healthy volunteers. Gastroenterology 1997; 112: A78